Pathstone Family Office’s DexCom DXCM Stock Holding History

Pathstone Family Office’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.02M	Buy	10,937 +7,807	+249%	+$880K	0.01%	698
2023 Q2	$448K	Buy	3,130 +282	+10%	+$34.1K	0.01%	797
2023 Q1	$331K	Sell	2,848 -15,524	-84%	-$1.74M	0.01%	874
2022 Q4	$1.41M	Buy	18,372 +7,465	+68%	+$820K	0.01%	621
2022 Q3	$878K	Buy	+10,907	New	+$924K	0.01%	808
2021 Q1	–	Sell	-56	Closed	-$5K	–	851
2020 Q4	$5K	Buy	+56	New	+$5K	﹤0.01%	947
2017 Q2	–	Sell	-32	Closed	-$1K	–	455
2017 Q1	$1K	Buy	+32	New	+$625	﹤0.01%	451
2014 Q4	–	Sell	-280	Closed	-$3K	–	153
2014 Q3	$3K	Buy	+280	New	+$2.86K	0.01%	278
2014 Q2	–	Sell	-272	Closed	-$3K	–	144
2014 Q1	$3K	Buy	+272	New	+$2.81K	0.01%	142
2013 Q4	–	Sell	-3,992	Closed	-$28K	–	241
2013 Q3	$28K	Buy	+3,992	New	+$25.3K	0.12%	110

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Pathstone Family Office's DXCM Position: Q3 2023 in Review

Pathstone Family Office increased its DexCom (DXCM) stake by 249% in Q3 2023, buying an estimated $880K and bringing the position to 10,937 shares worth $1.02M. The position accounts for 0.01% of the portfolio, ranked #698.

Pathstone Family Office first reported a position in DXCM in Q3 2013 and has held it in 10 quarters since. The position peaked at $1.41M in Q4 2022. 903 funds tracked by Wall St. Rank hold DXCM as of Q3 2023.

Pathstone Family Office held 10,937 shares of DexCom worth $1.02M as of Q3 2023.
Pathstone Family Office bought 7,807 DexCom shares in Q3 2023, an estimated $880K.
DexCom made up 0.01% of Pathstone Family Office's portfolio in Q3 2023, its #698 holding.
Pathstone Family Office first reported a position in DexCom in Q3 2013 and has held it in 10 quarters since.
Pathstone Family Office's DexCom position peaked at $1.41M in Q4 2022.
903 funds tracked by Wall St. Rank held DexCom as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.